Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK-4830 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Lenvatinib; Paclitaxel; Pemetrexed
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms MK-4830-001
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 30 Apr 2025 Results (At data cutoff: 19 Sept 2024) assessing safety and efficacy for MK-4830 plus pembro plus chemotherapy (chemo) for select cohorts J. K & L from the expansion phase, presented at the 116th Annual Meeting of the American Association for Cancer Research.
  • 16 May 2024 Planned End Date changed from 25 Oct 2025 to 28 Sep 2025.
  • 16 May 2024 Planned primary completion date changed from 25 Oct 2025 to 28 Sep 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top